Press coverage about Neuralstem (NASDAQ:CUR) has trended somewhat positive on Friday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neuralstem earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.2522408419782 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Neuralstem (NASDAQ:CUR) traded down $0.05 during mid-day trading on Friday, hitting $1.87. The stock had a trading volume of 196,600 shares, compared to its average volume of 367,967. The firm has a market capitalization of $28.32, a price-to-earnings ratio of -1.13 and a beta of 1.60. Neuralstem has a fifty-two week low of $0.88 and a fifty-two week high of $6.60.
TRADEMARK VIOLATION WARNING: “Neuralstem (CUR) Getting Somewhat Positive Media Coverage, Analysis Shows” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3126967/neuralstem-cur-getting-somewhat-positive-media-coverage-analysis-shows.html.
Neuralstem Company Profile
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with MarketBeat.com's FREE daily email newsletter.